Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Effort To Close Patent Loophole Seen Affecting Indian Generics

This article was originally published in PharmAsia News

Executive Summary

Indian generics makers are expected to be among the most-affected by a U.S. decision to plug loopholes that allow brand-generic patent deals. The deals often involve a brand-name drug maker and generics makers reaching agreements to settle patent disputes. Ranbaxy Laboratories and Dr. Reddy's Laboratories have been involved in several settlements with major pharmas, helping to spark the U.S. Federal Trade Commission concern about anti-competitive practices. The agency threatened action to prevent the primary effect of the deals, which the FTC says delays the availability of the cheaper generics on the U.S. market. The action could include legislation to amend current law that allows the deals. (Click here for more

You may also be interested in...



Japanese Firms Pursued Over Edirol Ingredient

Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.

Who’s Hired? Apotex Names New US President & CEO

As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles. 

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel